Our Stock of the Week is ABIVAX Societe Anonyme (ABVX). Abivax is a clinical-stage biotechnology company headquartered in Paris, France, with a US office in Waltham, Massachusetts. Its primary focus is on inflammatory bowel disease (IBD), starting with ulcerative colitis (UC) and expanding into Crohn’s disease (CD). The company’s lead drug candidate is obefazimod (also known as ABX464), an investigational, oral, once-daily therapy.
What makes Obefazimod unique is its mechanism of operation. ABIVAX describes it as the first molecule designed to enhance microRNA-124 (miR-124), a natural regulator of inflammatory signaling. In simple terms, the drug is intended to help “normalize” inflammatory pathways rather than simply bludgeon the immune system.
In July, ABIVAX reported positive Phase 3 results from two 8-week UC induction studies that met the FDA primary endpoint of clinical remission at Week 8 (50 mg once daily). In biotech terms, this is a meaningful “de-risking” event because it moves the debate from “does the drug work at all?” to “how durable is it, what does safety look like over time, and how does it compete commercially?”
ABIVAX is positioning obefazimod as a differentiated, orally administered, once-daily option. If longer-duration data support a strong benefit/risk profile, that combination can translate into real-world adoption potential in a very large market. ABIVAX has also initiated Crohn’s disease development, and is expecting data in 2H 2026.
According to TheFly.com, recent analyst coverage is Truist with a Buy, $140 target on Nov. 24, 2025. Barclays with an Overweight and $142 target on Oct. 13, 2025, and Wolfe Research with an Outperform and $176 target (early Nov. 2025).
Technically, the stock pulled back recently from a high of $130 to support around $110. $110 is the key level currently, and we are using that as our initial threshold for the trade. ABIVAX is an attractive setup because it has both a credible clinical narrative that can re-rate in stages, combined with a chart that offers a clean way to define risk. With ABVX holding support near $110, we look to structure the position around an objective technical “line in the sand,” rather than relying on hope or headline-chasing. As always, we are looking to aggressively trade the stock as the chart develops.
This post is for educational purposes only! This is not advice or a recommendation. We do not give investment advice. Do not act on this post. Do not buy, sell, or trade the stocks mentioned herein. We WILL actively trade this stock differently than discussed herein. We will sell into strength and buy or sell at any time for any reason. We will actively trade into any unusual activity. At the time of this post, principals, employees, and affiliates of Shark Investing, Inc. and/or principals, clients, employees, and affiliates of Hammerhead Financial Strategies, LLC, directly or indirectly, controlled investment and/or trading accounts containing positions in ABVX. To accommodate the objectives of these investing and/or trading accounts, the trading in these shares will be contrary to and/or inconsistent with the information contained in this posting.
